VIA-3196: Phase I data

A double-blind, placebo-controlled, U.S. Phase I trial in 72 healthy volunteers showed that single ascending-doses of up to 200 mg oral MDL-3916 were well tolerated. The maximum tolerated dose (MTD) was not reached. Data were presented at the American Heart Association meeting in Los Angeles. ...